Sector News

Merck KGaA’s deputy chief Oschmann set to become CEO – Manager Magazin

March 20, 2015
Life sciences
(Reuters) – Germany’s Merck KGaA will promote its deputy chief executive, Stefan Oschmann, to the top job next year to replace Karl-Ludwig Kley, Manager Magazin reported on Friday, citing company sources.
 
The publication said Oschmann, 57, would take on the new role after the group’s annual shareholder meeting in April 2016 or in September next year at the latest, when Kley’s current contract expires.
 
The German drugs and chemicals maker last September appointed Oschmann, the head of its pharma business at the time, as deputy chief executive from January, sharing strategic management functions and representation of the company with Kley, who is 63.
 
A Merck spokeswoman said a decision on Kley’s succession has not yet been made and that this would be a matter for the family-controlled group’s board of partners. She declined to comment further.
 
Merck, which is also the world’s largest maker of liquid crystals for flat-panel displays, is buying Sigma-Aldrich , putting it on track to become the world’s second-largest lab supplies maker after Thermo Fisher.
 
Before joining Merck KGaA in 2011, German-born Oschmann was in charge of Merck & Co Inc’s emerging markets operations. The two companies share historic roots but are under separate ownership since World War One. (Reporting by Georgina Prodhan; Editing by Ludwig Burger and Greg Mahlich)

comments closed

Related News

July 21, 2024

CordenPharma invests €900m in peptide platform expansion

Life sciences

CordenPharma announced its largest strategic investment to date, committing to spend ~€900m over the next three years to enhance its peptide technology platform. The planned investment consists of two major expansion initiatives occurring in parallel in the US and Europe, including both existing facilities and new constructions.

July 21, 2024

DSM-Firmenich to sell MEG-3 fish oil business to KD Pharma Group

Life sciences

DSM-Firmenich has announced the sale of its MEG-3 fish oil business to KD Pharma Group, a contract development and manufacturing organisation that is active in pharmaceutical and nutritional lipids. As part of the transaction, DSM-Firmenich will obtain a minority stake of 29% in KD Pharma’s parent company O³ Holding GmbH.

July 21, 2024

Veranova appoints Cécile Maupas as Senior Vice President, Chief Commercial Officer

Life sciences

Veranova, a development and manufacturing of specialist and complex APIs for the pharmaceutica l and biotech sectors, recently announced the appointment of Cécile Maupas as Senior Vice President, Chief Commercial Officer. Cécile will join the executive team and assume responsibility for business development, marketing, project management, commercial operations, and product management.

How can we help you?

We're easy to reach